Clinical trials: CDA
Relapsing-Remitting Multiple Sclerosis
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
- Trial name
- NCT04997148
- Where
- 8 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Cigarette Use, Alcohol Use Above Recommended Limits
Developing a Team-Delivered Intervention for Smoking and Hazardous Drinking for Primary Care Veterans With Cardiovascular Diseases
In this study, the investigators are interested in learning how patients feel about and are impacted by a new approach for the primary care team to use to talk to patients about heart disease and health behaviors.
- Conditions
- Cigarette Use, Alcohol Use Above Recommended Limits, Cardiovascular Risk Factors (e.g., Hypertension), Cardiovascular Diseases
- Trial name
- CARE (NCT05275582)
- Testing
- CARE
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Depression
Improving Depression Management
Depression is disabling and affects one in five Veterans. VA's Primary Care-Mental health Integration (PC-MHI) enables specialists to support medication treatment in primary care, but timely and sufficient access to psychotherapy…
- Trial name
- IDMPC (NCT05050227)
- Testing
- cCBT Enhanced Collaborative Care, Usual Care
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- VA Office of Research and Development
Tobacco Use
Tobacco Cessation Treatment Preferences Among Veteran Smokers
There are significant barriers to tobacco cessation treatment for patients and providers in specialty care clinical settings. Specialty providers cite several barriers to delivering evidence-based tobacco cessation care…
- Trial name
- MESH (NCT05277207)
- Testing
- Personalized Smoking Cessation Facilitation Meetings, Personalized Smoking Cessation Pharmacotherapy, Personalized Text Messaging Support
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple…
- Trial name
- CLOCK-MS (NCT03963375)
- Testing
- Cladribine
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Gregory Wu
Multiple Sclerosis
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
The main aim was to study in the real world setting the effectiveness of Cladribine tablets in terms of Annualized Relapse Rate (ARR) and disability progression, in participants who switched from a first line Disease Modifying…
- Trial name
- NCT04934800
- Testing
- Cladribine
- Where
- 61 sites in Austria, Greece and 5 more
- Volunteers
- 256 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- CLARITY (NCT00213135)
- Testing
- Cladribine 5.25 mg/kg, Cladribine 3.5 mg/kg
- Volunteers
- 1,326 people
- Sponsor
- EMD Serono
Acute Myeloid Leukemia
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
This phase I/II trial studies the side effects and best dosing frequency of gemtuzumab ozogamicin when given in combination with granulocyte colony stimulating factor (G-CSF), cladribine, cytarabine and mitoxantrone (GCLAM) and…
- Trial name
- NCT03531918
- Testing
- Cladribine, Cytarabine, Gemtuzumab Ozogamicin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Fred Hutchinson Cancer Center
Fatty Liver
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The study is designed to investigate the relationship between insulin resistance and non-alcoholic fatty liver disease (NAFLD) and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining…
- Trial name
- NCT01289639
- Testing
- fenofibrate, pioglitazone
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
This phase I/II trial studies the side effects and best dose of mitoxantrone hydrochloride when given together with filgrastim, cladribine, and cytarabine and to see how well they work in treating patients with acute myeloid…
- Conditions
- Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
- Trial name
- NCT02044796
- Testing
- Cladribine, Cytarabine, Filgrastim
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Fred Hutchinson Cancer Center
Obesity, Patient Education
Teaching Obesity Treatment Options to Adult Learners Trial
Obesity is the second leading cause of death in the U.S. The treatment of obesity and its related health issues, including cardiovascular disease and diabetes, exceeds $150 billion annually.
- Conditions
- Obesity, Patient Education, Weight Loss
- Trial name
- TOTAL (NCT03856320)
- Testing
- Educational Video
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- VA Office of Research and Development
Stroke, TIA
Reducing Risk of Recurrence
Adults who have had a previous stroke or transient ischemic attack (TIA) remain at risk for having a second serious event, especially if they have uncontrolled blood pressure or cholesterol.
- Conditions
- Stroke, TIA, Hypertension, Hyperlipidemia
- Trial name
- RRR (NCT01122394)
- Testing
- TI, AP
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Oral Cladribine B-cell Study
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells and Tregs
- Trial name
- NCT06415864
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Queen Mary University of London
Relapsing-Remitting Multiple Sclerosis
CLARITY Extension Study
The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY).
- Trial name
- NCT00641537
- Testing
- Cladribine
- Where
- 116 sites in United States, Australia and 29 more
- Volunteers
- 867 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Cardiovascular Disease
Heart Health Buddies: Peer Support to Decrease CVD Risk
This pilot study will use a hybrid reciprocal peer support and peer coach model to initiate and sustain heart-healthy behavioral changes in Veterans.
- Trial name
- HHB (NCT03646656)
- Testing
- reciprocal peer support and non reciprocal coach support
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
Physical Activity
Social and Financial Incentives to Increase Physical Activity Among Overweight and Obese Veterans
In this randomized, controlled trial the investigators will compare the use of social and financial incentive-based interventions to increase physical activity among overweight and obese Veterans during a 12-week intervention…
- Trial name
- NCT03563027
- Testing
- Social Incentive Gamification, Support Sponsor, Financial Incentive
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
The purpose of the study is to assess the influence of pantoprazole on the pharmacokinetic profile of cladribine, especially in terms of extent of absorption of cladribine since pH-modifying drug may potentially affect the…
- Trial name
- NCT00938366
- Testing
- Cladribine, Pantoprazole
- Volunteers
- 18 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Human Immunodeficiency Virus, Smoking
Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)
Smoking is a significant cause of damage to health and quality of life specifically for Veterans with human immunodeficiency virus (HIV). Smoking cessation interventions for this population are lacking.
- Trial name
- MESH (NCT04135937)
- Testing
- Bupropion, Varenicline, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of filgrastim (granulocyte colony-stimulating factor [G-CSF]), cladribine, cytarabine, and mitoxantrone, when given together with sorafenib and to see how well they…
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Trial name
- NCT02728050
- Testing
- Cladribine, Cytarabine, Filgrastim
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Washington
Prediabetes
INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)
This study will evaluate a VA MyHealtheVet Secure Messaging intervention that uses different intervention messaging strategies designed to increase engagement in behaviors to prevent type 2 diabetes.
- Trial name
- INVENT (NCT03403231)
- Testing
- INVENT Secure Messaging Intervention
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development